Zevra Therapeutics Presented New Data for Arimoclomol and OLPRUVA® (Sodium Phenylbutyrate) at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual SymposiumGlobeNewsWire • 09/06/24
Zevra Therapeutics (ZVRA) Reports Q2 Loss, Tops Revenue EstimatesZacks Investment Research • 08/13/24
Zevra Therapeutics Announces Pricing of Underwritten Offering of Common StockGlobeNewsWire • 08/09/24
Zevra Therapeutics to Present at Canaccord Genuity's 44th Annual Growth ConferenceGlobeNewsWire • 08/07/24
Earnings Preview: Zevra Therapeutics (ZVRA) Q2 Earnings Expected to DeclineZacks Investment Research • 08/06/24
FDA Advisory Committee Votes Favorably that the Data Support Arimoclomol as Effective Treatment for Patients with Niemann-Pick Disease Type CGlobeNewsWire • 08/02/24
Zevra Therapeutics (ZVRA) Surges 21.9%: Is This an Indication of Further Gains?Zacks Investment Research • 07/10/24
Zevra Therapeutics Transitions to Orsini as the Specialty Pharmacy Provider for OLPRUVA® (sodium phenylbutyrate), a Treatment for Certain Urea Cycle DisordersPRNewsWire • 06/18/24
Zevra Therapeutics Announces Positive Final Results from Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at SLEEP 2024 Annual MeetingGlobeNewsWire • 06/03/24
Zevra Therapeutics (ZVRA) Reports Q1 Loss, Lags Revenue EstimatesZacks Investment Research • 05/08/24
Zevra Therapeutics Reports First Quarter 2024 Financial Results and Corporate UpdatesGlobeNewsWire • 05/08/24
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRAPRNewsWire • 05/06/24
Zevra Therapeutics' President and Chief Executive Officer Issues Letter to Stockholders Highlighting Recent Key Accomplishments and Outlook for 2024GlobeNewsWire • 04/29/24
Zevra Therapeutics Presents New Data on the Long-Term Safety and Efficacy of Arimoclomol as a Treatment for Niemann-Pick Disease Type C at the SIMD 45th Annual MeetingGlobeNewsWire • 04/15/24
Zevra Therapeutics Refinances Existing Debt with up to $100M in Committed Capital under New Credit FacilityGlobeNewsWire • 04/10/24
Zevra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate UpdatesGlobeNewsWire • 03/28/24